Take­da wins pri­or­i­ty re­view for $400M col­orec­tal can­cer drug, li­censed from Hutchmed in Jan­u­ary

Take­da and Hutchmed scored a pri­or­i­ty re­view Thurs­day af­ter­noon for a col­orec­tal can­cer drug, the com­pa­nies an­nounced.

The ex­per­i­men­tal drug in ques­tion is fruquin­tinib, pre­vi­ous­ly ap­proved in Chi­na in 2018 to treat metasta­t­ic col­orec­tal can­cer. Take­da and Hutchmed are aim­ing to bring fruquin­tinib to the US and oth­er coun­tries out­side Chi­na in the same in­di­ca­tion, and the FDA set its de­ci­sion date for Nov. 30 of this year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER